Reply to: Treatment Intensification Based on Residual Disease in Elderly Patients With AML ...

Therapy for Stage IV Non–Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2024.3 ...

The India State-Level Disease Burden Initiative partners revealed significant variation in age-standardized incidence of the top 10 malignancies, including LC from 1990 to 2016. In men, the crude LC ...

Co-Occurrence of Cytogenetic Abnormalities and High-Risk Disease in Newly Diagnosed and Relapsed/Refractory Multiple Myeloma A total of 121 patients (previous ICI-treated cohort, n = 31, and each of ...

Efficacy of 177Lu-PSMA-617 with or without ARPIs for the treatment of mCRPC: VISION secondary analysis. Safety profile of lutetium-177 in patients with impaired renal function: A retrospective ...

Where Is the Future of Adjuvant Therapy for Hepatocellular Carcinoma? The following represents disclosure information provided by authors of this manuscript. All relationships are considered ...

Novel urine-enriched RNA panel (EPCAM, TTC3, H4C5) to detect prostate cancer and differentiate it from benign prostatic disease. This is an ASCO Meeting Abstract from the 2025 ASCO Genitourinary ...

How Should We Manage the Impact of Antimicrobial Resistance in Patients With Cancer? An Oncological and Infectious Disease Specialist Point of View ...

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I ...

Metastasis-directed therapy (MDT) plus androgen deprivation therapy (ADT) for oligometastatic prostate cancer (omPC): Primary results of the EXTEND continuous ADT (cADT) basket plus combined analysis ...

Safety profile of lutetium-177 in patients with impaired renal function: A retrospective analysis of adverse events in mCRPC treatment. This is an ASCO Meeting Abstract from the 2025 ASCO ...